MX2022014468A - Tratamiento para la amiloidosis. - Google Patents
Tratamiento para la amiloidosis.Info
- Publication number
- MX2022014468A MX2022014468A MX2022014468A MX2022014468A MX2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A
- Authority
- MX
- Mexico
- Prior art keywords
- amyloidosis
- treatment
- compounds
- formula
- amyloid
- Prior art date
Links
- 206010002022 amyloidosis Diseases 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010016202 Familial Amyloidosis Diseases 0.000 abstract 2
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 208000017105 hereditary amyloidosis Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027194P | 2020-05-19 | 2020-05-19 | |
| PCT/US2021/032808 WO2021236543A1 (en) | 2020-05-19 | 2021-05-17 | Treatment for amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014468A true MX2022014468A (es) | 2023-02-09 |
Family
ID=78708017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014468A MX2022014468A (es) | 2020-05-19 | 2021-05-17 | Tratamiento para la amiloidosis. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230210846A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4138837A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023527741A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230013102A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116133661A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021273731A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022023486A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183746A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298297A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014468A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202207931A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021236543A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024546584A (ja) * | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL316472A (en) * | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| US20210154368A1 (en) * | 2018-04-09 | 2021-05-27 | Case Western Reserve University | Bioink and crosslinkable support medium for printing |
| US10659731B2 (en) * | 2018-04-10 | 2020-05-19 | Facebook, Inc. | Automated cinematic decisions based on descriptive models |
| US10526132B2 (en) * | 2018-04-10 | 2020-01-07 | Dow Global Technologies Llc | Dispenser for can with fixed valve stem housing |
-
2021
- 2021-05-17 CN CN202180060027.8A patent/CN116133661A/zh active Pending
- 2021-05-17 KR KR1020227044559A patent/KR20230013102A/ko not_active Withdrawn
- 2021-05-17 WO PCT/US2021/032808 patent/WO2021236543A1/en not_active Ceased
- 2021-05-17 EP EP21807581.0A patent/EP4138837A4/en active Pending
- 2021-05-17 CA CA3183746A patent/CA3183746A1/en active Pending
- 2021-05-17 BR BR112022023486A patent/BR112022023486A2/pt not_active Application Discontinuation
- 2021-05-17 AU AU2021273731A patent/AU2021273731A1/en not_active Abandoned
- 2021-05-17 IL IL298297A patent/IL298297A/en unknown
- 2021-05-17 JP JP2022570279A patent/JP2023527741A/ja active Pending
- 2021-05-17 US US17/998,920 patent/US20230210846A1/en not_active Abandoned
- 2021-05-17 MX MX2022014468A patent/MX2022014468A/es unknown
- 2021-05-19 TW TW110118106A patent/TW202207931A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021236543A1 (en) | 2021-11-25 |
| JP2023527741A (ja) | 2023-06-30 |
| IL298297A (en) | 2023-01-01 |
| US20230210846A1 (en) | 2023-07-06 |
| BR112022023486A2 (pt) | 2023-01-10 |
| CN116133661A (zh) | 2023-05-16 |
| KR20230013102A (ko) | 2023-01-26 |
| AU2021273731A1 (en) | 2022-12-15 |
| TW202207931A (zh) | 2022-03-01 |
| EP4138837A4 (en) | 2024-05-22 |
| EP4138837A1 (en) | 2023-03-01 |
| CA3183746A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE548354T1 (de) | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen | |
| EA202092248A1 (ru) | Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими | |
| CR20240120A (es) | Compuesto inductor de la degradación de PLK1 novedoso | |
| TW200730523A (en) | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation | |
| MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
| MX2022003537A (es) | Terapias de combinacion. | |
| EP3914604A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT, PREVENTION OR REVERSE OF AGE-RELATED INFLAMMATION AND DISEASE | |
| TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
| MX2022013006A (es) | Inhibidor de bcl-2. | |
| SA521430751B1 (ar) | Kcnt1 مثبطات وطرق استخدامها | |
| MY209340A (en) | Egfr inhibitor for the treatment of cancer | |
| UA92355C2 (en) | urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS | |
| NO20080942L (no) | Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE) | |
| BRPI0517135A (pt) | composições e métodos para tratar doenças neoplásticas | |
| CY1124762T1 (el) | Αναστολεις πρωτεïνης δεσμευσης creb (cbp) | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| DE602005025517D1 (de) | Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas | |
| WO2008137102A3 (en) | Methods of modulating amyloid beta and compounds useful therefor | |
| CR20240296A (es) | Inhibidores parp1 | |
| SA522441857B1 (ar) | مركبات ربط سيريبلون، توليفات منها، وطرق للمعالجة باستخدامها | |
| MX2022002751A (es) | Tratamiento de la abstinencia de opioides. | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2021005972A (es) | Butirato alimenticio para tratar o prevenir un trastorno alergico. | |
| WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer |